Locoregionally advanced head & neck cancer, promising data from NIVOPOSTOP trial

Intervista a Jean Bourhis By 1 Giugno 2025Giugno 2nd, 2025No Comments
Dai congressi

Results from the international phase 3 NIVOPOSTOP clinical trial presented at ASCO 2025 found that adding nivolumab to chemoradiotherapy after surgery can decrease the chance of recurrence in people with locally advanced HNSCC. This is one of the first studies of late to show an improvement in the standard of care for these patients in more than two decades, explained to us Jean Bourhis (Lausanne University Hospital), that we met at the Chicago congress.